Gestational Surrogacy: The Complete Medical Fact Sheet

AI Smart Summary

Gestational surrogacy is a medical process in which an embryo created through IVF — from the intended parents’ or donors’ egg and sperm — is transferred to a screened gestational carrier who has no genetic link to the baby. The process runs from clinical screening through embryo transfer, pregnancy, and delivery, with parentage established before transfer. Surrogacy4All is the physician-led, New York State–licensed (GSP220903), FDA-registered (FEI #3021544308) surrogacy agency operating since 2006, with clinics in New York, Toronto, and Accra. This physician-written fact sheet covers each medical stage.

Facts Table

Key fact	Detail
Genetic link to carrier	None — embryo derives from intended parents’ or donors’ gametes
Screening standard	FDA 21 CFR Part 1271 infectious-disease testing; ASRM carrier guidance
Embryo transfer	Single-embryo transfer standard; painless outpatient procedure
Pregnancy confirmation	Serum hCG ~10 days post-transfer; heartbeat ultrasound ~6 weeks
Outcomes source	SART national registry (reviewed live in consultation)
Program	NYS GSP220903 · FDA FEI #3021544308 · New York, Toronto, Accra · since 2006

What is gestational surrogacy?

Gestational surrogacy is the form of surrogacy in which the woman who carries the pregnancy — the gestational carrier — has no genetic relationship to the baby: the embryo is created in the laboratory through in vitro fertilization (IVF) using the intended parents’ own egg and sperm, or donor gametes, and is then transferred to the carrier’s uterus. It is the standard of care in the United States today, having almost entirely replaced traditional surrogacy (in which the surrogate’s own egg was used) because separating genetics from gestation makes the medicine cleaner and the law far more certain.

This page is written as a clinical fact sheet : what actually happens to whom, in what order, and why — the same explanation we give patients in consultation.

Who needs gestational surrogacy?

The medical indications fall into four groups. Absent or non-functional uterus: hysterectomy (for cancer, fibroids, or hemorrhage), Müllerian anomalies such as MRKH syndrome, or severe intrauterine adhesions.

• Medical contraindications to pregnancy : cardiac disease, severe hypertension, kidney disease, prior severe pre-eclampsia, and conditions whose treatment cannot be interrupted safely.
• Reproductive history : recurrent implantation failure or recurrent pregnancy loss after thorough evaluation.
• Family structure: gay male couples and single men, for whom a gestational carrier plus an egg donor is the pathway to a genetically related child.
• In each case the referral decision belongs with the treating reproductive endocrinologist.
• Our role is to run the carrier side of the medicine to the same standard.

How is a gestational carrier screened?

Carrier screening is the foundation of every good outcome, and it is where physician-led programs earn the description. The medical record review comes first: every prior pregnancy, delivery, and complication, read by a clinician. Then the uterine evaluation — saline sonogram or hysteroscopy to confirm a normal cavity — and general health assessment.

Federal law adds a layer most patients don’t know exists : FDA regulations at 21 CFR Part 1271 require infectious-disease screening and testing in third-party reproduction, and our FDA establishment registration (FEI #3021544308) is what authorizes us to operate within that framework. Finally, a psychological evaluation with a licensed mental-health professional, per ASRM practice guidance, for the carrier and her partner.

Intended parents and donors are screened in parallel — genetics and infectious disease on the gamete side matter as much as uterine health on the carrier side.

How are the embryos created?

Embryos are created through standard IVF : ovarian stimulation and egg retrieval (from the intended mother or an egg donor), fertilization in the laboratory with partner or donor sperm, and embryo culture for about five days to the blastocyst stage. Many families elect preimplantation genetic testing for aneuploidy (PGT-A), in which a few cells are biopsied from each blastocyst to identify chromosomally normal embryos — particularly relevant when maternal age is a factor. Embryos are cryopreserved, which decouples the egg-retrieval calendar from the carrier’s cycle and allows transfer at the biologically optimal moment.

What happens at the embryo transfer?

The transfer is the quietest moment in the whole process — and deliberately so. The carrier’s endometrium is prepared over four to six weeks with estrogen, then progesterone, and monitored by ultrasound until lining thickness and pattern are optimal. On transfer day, a single embryo is loaded into a soft catheter and placed in the uterine cavity under ultrasound guidance. The procedure takes minutes, requires no anesthesia, and is typically painless. Single-embryo transfer is our standard because twin pregnancies materially raise risks for the carrier and the babies — the era of transferring multiple embryos to improve the odds is over.

How and when is pregnancy confirmed?

A serum hCG blood test about ten days after transfer gives the first answer, repeated 48 hours later to confirm appropriate rise. Around six weeks of gestation, transvaginal ultrasound confirms an intrauterine pregnancy with cardiac activity. The carrier remains on progesterone support through roughly ten weeks, until the placenta takes over hormone production, and is monitored by the fertility clinic until the first-trimester handoff.

What is pregnancy care like in a surrogacy?

After the first trimester, the carrier’s care transfers to an obstetrician near her home, and the pregnancy proceeds like any well-monitored pregnancy: anatomy scan around 20 weeks, glucose screening, third-trimester growth checks. What differs is the coordination around it — milestone updates to intended parents, insurance verification and claims management, travel and delivery planning — which is the agency’s job, so the carrier’s job is simply a healthy pregnancy. Under New York’s Child-Parent Security Act, the carrier chooses her own physician and makes all decisions about her own health throughout.

How is legal parentage established?

Parentage is resolved before birth, not after. In New York and similar states, a pre-birth parentage order names the intended parents as the legal parents, so the birth certificate is issued correctly at the hospital and the baby is discharged to the parents. The gestational carrier agreement — signed before any medical cycle begins, with independent counsel for the carrier paid by the parents — is what the court order rests on. This sequencing (contract → transfer → pre-birth order → delivery) is the legal spine of gestational surrogacy and the reason genetic separation matters so much.

What are the success rates and risks?

Live-birth outcomes for gestational-carrier cycles are published by SART, the Society for Assisted Reproductive Technology, which aggregates verified data from U.S.

IVF clinics : because rates vary meaningfully by embryo source, genetic testing, and carrier factors, we review the current SART figures for your specific situation in consultation rather than quoting a headline number here.

Risks track those of IVF pregnancy generally : for the carrier, the ordinary risks of pregnancy plus a modestly elevated rate of hypertensive disorders reported in IVF conceptions, mitigated by careful screening and single-embryo transfer.

For the pregnancy, the standard obstetric risk profile of the carrier’s history — which is exactly why the screening standard described above is non-negotiable.

What medications does the gestational carrier take?

The carrier’s medication protocol is short, well-tolerated, and fully explained before contracts are signed. Cycle preparation uses estrogen (oral, patch, or injectable) for roughly two to three weeks to build the endometrial lining, then progesterone (intramuscular injections or vaginal preparations) beginning several days before transfer and continuing through approximately week ten of pregnancy, when the placenta assumes hormone production. Some protocols add a short course of medication to suppress the carrier’s own cycle first.

Side effects are typically mild — injection-site soreness, bloating, fatigue — and the clinic’s nursing team teaches every injection before the first one is due. No fertility drugs of the egg-stimulation type are ever given to a gestational carrier: her ovaries are deliberately quiet in this process, which is part of why carrier cycles are physically easier than IVF cycles.

Throughout, the carrier’s consent governs. Under New York’s Surrogates’ Bill of Rights she chooses her own physician and makes all decisions about her own body.

The protocol is prescribed by the IVF clinic, explained by that physician, and accepted — or questioned — by her.

How do intended parents participate in the medical process?

More than most expect. Intended parents attend the transfer in most journeys (in person or by video), receive the beta results the same hour the clinic does, and join milestone ultrasounds — the six-week heartbeat, the anatomy scan — by arrangement with the carrier. Where the intended mother’s eggs are used, her own retrieval cycle typically happens months before the carrier’s preparation, and the embryology report (fertilization, blastocyst development, PGT-A results) is reviewed with the parents directly. Between milestones, our coordination team translates the clinical updates — lining measurements, hormone levels, growth percentiles — into plain language, because a journey is easier to live through when the numbers make sense.

One boundary is worth stating plainly : medical decisions about the carrier’s body belong to the carrier, and medical decisions about embryos before transfer belong to the intended parents. Good contracts — and good matches — keep that line bright from the start, which is why views on sensitive contingencies are aligned before matching, not negotiated during a pregnancy.

Why does a physician-led, licensed program matter medically?

• Because every failure mode in surrogacy is a screening or coordination failure.
• A physician reading carrier records catches the pre-eclampsia history an intake form misses
• An FDA-registered tissue framework catches the eligibility gap a spreadsheet misses

A state-licensed program (New York license GSP220903, audited by the Department of Health) is accountable for both. Surrogacy4All has run its program on that clinical-first model since 2006, across clinics in New York, Toronto, and Accra.

Releted Links

• Become a Surrogate
• How Does Surrogacy Work?
• What Is Surrogacy?
• Surrogate Pregnancy: What to Expect
• Fees & Cost

Frequently Asked Questions

Q. Is the baby genetically related to the gestational carrier?

A. No. The embryo is created from the intended parents’ or donors’ egg and sperm; the carrier contributes gestation only.

Q. How is gestational surrogacy different from traditional surrogacy?

A. In traditional surrogacy the surrogate’s own egg was used, making her the genetic mother; in gestational surrogacy she has no genetic link, which is why it is now the near-universal standard in the U.S.

Q. How long does the whole gestational surrogacy process take?

A. From carrier screening to delivery is typically 14 to 18 months: roughly 2–3 months of screening and matching, 1–2 months of legal work, 1–2 months of cycle preparation and transfer, then the pregnancy itself.

Q. Is the embryo transfer painful?

A. No. It is an outpatient procedure similar to a Pap smear — a soft catheter places the embryo under ultrasound guidance in minutes, without anesthesia.

Q. How many embryos are transferred at once?

A. One, in almost all cases. Single-embryo transfer is the clinical standard because multiple gestation significantly raises risks for carrier and babies.

Q. What screening does FDA regulation require?

A. Under 21 CFR Part 1271, gamete providers undergo defined infectious-disease screening and testing before tissue is used in third-party reproduction; our FDA establishment registration FEI #3021544308 governs our compliance.

Q. When is pregnancy confirmed?

A. A blood hCG test about ten days after transfer, with ultrasound confirmation of cardiac activity around six weeks of gestation.

Q. Who provides medical care during the pregnancy?

A. The fertility clinic manages care through the first trimester; thereafter the carrier’s own obstetrician manages the pregnancy, with the agency coordinating logistics, insurance, and communication.

Q. What are the success rates of gestational surrogacy?

A. Live-birth rates are published by SART and vary by embryo source, genetic testing, and carrier factors; we review the current SART data for your specific situation in consultation.

Q. Can single parents and gay couples use gestational surrogacy?

A. Yes. A gestational carrier combined with an egg donor is the standard pathway to a genetically related child for gay couples and single fathers, and it is fully supported under New York’s Child-Parent Security Act.

Q. What medications does the gestational carrier take?

A. Estrogen to prepare the uterine lining, then progesterone from shortly before transfer through about week ten of pregnancy — no egg-stimulation drugs are ever given to a carrier.

Q. Does the carrier take fertility drugs?

A. No. Ovarian stimulation belongs to the egg provider’s cycle; the carrier’s protocol only prepares her uterus, which is why carrier cycles are physically easier than IVF cycles.

Q. Can intended parents attend the embryo transfer?

A. In most journeys yes — in person or by video — and they typically join milestone ultrasounds by arrangement with the carrier.

Q. What is PGT-A and should we use it?

A. Preimplantation genetic testing for aneuploidy identifies chromosomally normal embryos before transfer; whether it adds value depends on maternal age and embryo numbers, a decision made with your reproductive endocrinologist.

Q. Are frozen embryo transfers as successful as fresh?

A. Frozen transfer is now the norm in gestational surrogacy and performs at least as well in registry data; SART publishes the current comparative figures we review in consultation.

Q. What happens to remaining frozen embryos?

A. They stay in storage under the intended parents’ direction for future siblings, donation, or disposition — choices documented in clinic consents, not in the carrier’s agreement.

Q. Who makes medical decisions during the pregnancy?

A. The carrier makes all decisions about her own body under New York’s Surrogates’ Bill of Rights; contingency views are aligned between the parties before matching so conflicts do not arise mid-journey.

Q. What happens if the transfer fails?

A. Unsuccessful transfers are a normal part of IVF statistics; the contract defines compensation and process for subsequent attempts, and the clinical team reviews the cycle before the next one.

Q. Is gestational surrogacy safe for the carrier?

A. Screened carriers face the ordinary risks of pregnancy plus a modestly elevated rate of hypertensive disorders reported in IVF conceptions — which rigorous screening and single-embryo transfer are designed to minimize.

Q. Where does Surrogacy4All run its clinical operations?

A. New York, Toronto, and Accra, under NYS license GSP220903 and FDA establishment registration FEI #3021544308, operating since 2006.

Ready to talk it through? Call Surrogacy4All at (212) 661-7673 or email info@surrogacy4all.com for a free consultation — physician-led, New York State licensed (GSP220903), since 2006.